Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.44 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.39 |
| ▸ | IARS1 | P41252 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19987310 | 0.89 | CYP3A4 (0.48) | CYP3A4CYP2C9ADORA3P2RX3P2RX2 | |
| SCHEMBL19987349 | 0.87 | CYP3A4 (0.44) | CYP3A4CYP2C9ADORA3DNPH1NT5E | |
| SCHEMBL19987160 | 0.87 | DNPH1 (0.46) | CYP3A4CYP2C9ADORA3DNPH1NT5E | |
| SCHEMBL19987319 | 0.85 | CYP3A4 (0.42) | CYP3A4CYP2C9ADORA3DNPH1NT5E | |
| SCHEMBL19987217 | 0.84 | CYP3A4 (0.48) | CYP3A4CYP2C9ADORA3BTN3A1 | |
| SCHEMBL19987378 | 0.84 | DNPH1 (0.44) | CYP3A4CYP2C9ADORA3DNPH1NT5E | |
| SCHEMBL19987195 | 0.83 | CYP3A4 (0.47) | CYP3A4CYP2C9NT5EBTN3A1 | |
| SCHEMBL26029321 | 0.81 | CYP3A4 (0.64) | CYP3A4CYP2C9ADORA3DNPH1NT5E | |
| SCHEMBL26029347 | 0.81 | CYP3A4 (0.64) | CYP3A4CYP2C9ADORA3DNPH1NT5E | |
| SCHEMBL26029344 | 0.81 | CYP3A4 (0.64) | CYP3A4CYP2C9ADORA3DNPH1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190322693-A1 | NUCLEOSIDE ANALOGUES AND METHODS OF USE THEREOF | LCB PHARMA INC. (CA) | 2019-10-24 | — | — | US | disclosed |
| WO-2018049535-A1 | NUCLEOSIDE ANALOGUES AND METHODS OF USE THEREOF | LCB PHARMA INC. (CA) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322693-A1 | NUCLEOSIDE ANALOGUES AND METHODS OF USE THEREOF | PNP, TYMP, MTAP | CYP3A4 3805/4885CYP2C9 4343/4885ADORA3 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.